1887

Abstract

Anaerobic bacterial infection is often accompanied by abscess formation; however, few studies have been published with descriptive data specifically evaluating antimicrobial activity in the presence of abscesses. The aim of this study was to establish a murine model of anaerobic infection with abscess formation and to verify the utility of this model for evaluating the efficacy of an antimicrobial agent. A clinical isolate of was inoculated into the caudal vein of immunocompetent BALB/c mice at 10 c.f.u. per mouse. Changes in body weight, bacterial load and histopathology of key organs were evaluated. After inoculation, bacterial counts in the liver increased from 10 to 10 c.f.u. after 1–3 days, and liver abscess formation was observed on the day following infection. Abscess formation and bacterial growth were not observed in other organs. In this model, 3 days of treatment with 5 mg metronidazole kg eradicated in the liver; however, a reduction in bacterial load was not observed with 0.05 mg metronidazole kg. In this study, we established a novel murine model of liver abscess via haematogenous infection that may be useful for investigating antimicrobial activity against anaerobic abscesses and understanding the pathogenesis of infection.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.062067-0
2013-11-01
2024-12-06
Loading full text...

Full text loading...

/deliver/fulltext/jmm/62/11/1755.html?itemId=/content/journal/jmm/10.1099/jmm.0.062067-0&mimeType=html&fmt=ahah

References

  1. Abe P. M., Lennard E. S., Holland J. W. 1976; Fusobacterium necrophorum infection in mice as a model for the study of liver abscess formation and induction of immunity. Infect Immun 13:1473–1478[PubMed]
    [Google Scholar]
  2. Brook I. 2012; Anaerobic bacteria in upper respiratory tract and head and neck infections: microbiology and treatment. Anaerobe 18:214–220 [View Article][PubMed]
    [Google Scholar]
  3. Ednie L. M., Appelbaum P. C. 2009; Antianaerobic activity of sulopenem compared to six other agents. Antimicrob Agents Chemother 53:2163–2170 [View Article][PubMed]
    [Google Scholar]
  4. Giamarellou H. 2000; Anaerobic infection therapy. Int J Antimicrob Agents 16:341–346 [View Article][PubMed]
    [Google Scholar]
  5. Hagelskjaer Kristensen L., Prag J. 2000; Human necrobacillosis, with emphasis on Lemierre’s syndrome. Clin Infect Dis 31:524–532 [View Article][PubMed]
    [Google Scholar]
  6. Hill G. B. 1977; Therapeutic evaluation of minocycline and tetracycline for mixed anaerobic infection in mice. Antimicrob Agents Chemother 11:625–630 [View Article][PubMed]
    [Google Scholar]
  7. Kuppalli K., Livorsi D., Talati N. J., Osborn M. 2012; Lemierre’s syndrome due to Fusobacterium necrophorum. Lancet Infect Dis 12:808–815 [View Article][PubMed]
    [Google Scholar]
  8. Narayanan S. K., Nagaraja T. G., Chengappa M. M., Stewart G. C. 2002; Leukotoxins of gram-negative bacteria. Vet Microbiol 84:337–356 [View Article][PubMed]
    [Google Scholar]
  9. Papaparaskevas J., Katsandri A., Pantazatou A., Stefanou I., Avlamis A., Legakis N. J., Tsakris A. 2011; Epidemiological characteristics of infections caused by Bacteroides, Prevotella and Fusobacterium species: a prospective observational study. Anaerobe 17:113–117 [View Article][PubMed]
    [Google Scholar]
  10. Riordan T. 2007; Human infection with Fusobacterium necrophorum (necrobacillosis), with a focus on Lemierre’s syndrome. Clin Microbiol Rev 20:622–659 [View Article][PubMed]
    [Google Scholar]
  11. Shinjo T., Fujisawa T., Mitsuoka T. 1991; Proposal of two subspecies of Fusobacterium necrophorum (Flügge) Moore and Holdeman: Fusobacterium necrophorum subsp. necrophorum subsp. nov., nom. rev. (ex Flügge 1886), and Fusobacterium necrophorum subsp. funduliforme subsp. nov., nom. rev. (ex Hallé 1898). Int J Syst Bacteriol 41:395–397 [View Article][PubMed]
    [Google Scholar]
  12. Tadepalli S., Narayanan S. K., Stewart G. C., Chengappa M. M., Nagaraja T. G. 2009; Fusobacterium necrophorum: a ruminal bacterium that invades liver to cause abscesses in cattle. Anaerobe 15:36–43 [View Article][PubMed]
    [Google Scholar]
  13. Tanaka K., Mikamo H., Nakao K., Ichiishi T., Goto T., Yamagishi Y., Watanabe K. 2009; In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. Antimicrob Agents Chemother 53:319–322 [View Article][PubMed]
    [Google Scholar]
  14. Tran C. M., Tanaka K., Yamagishi Y., Goto T., Mikamo H., Watanabe K. 2011; In vitro antimicrobial activity of razupenem (SMP-601, PTZ601) against anaerobic bacteria. Antimicrob Agents Chemother 55:2398–2402 [View Article][PubMed]
    [Google Scholar]
  15. Wilson J. R., Limaye A. P. 2004; Risk factors for mortality in patients with anaerobic bacteremia. Eur J Clin Microbiol Infect Dis 23:310–316 [View Article][PubMed]
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.062067-0
Loading
/content/journal/jmm/10.1099/jmm.0.062067-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error